Abstract
This study examines prescription drug launch prices over the last 2 decades and changes after the initiation of the Inflation Reduction Act.
Hariharan Shanmugam, Mark McGuire, Benjamin N. Rome
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
National trends in prescription drug expenditures and projections for 2025.
10.1093/ajhp/zxaf092 · 2025
Trends in prescription drug launch prices, 2008-2021.
10.1001/jama.2022.5542 · 2022
The growing success of Medicare drug-price negotiation.
10.1056/nejmp2517584 · 2026
Cancer drug access and innovation under the inflation reduction act—a balancing act.
10.1001/jamaoncol.2024.4745 · 2024
Correlation between changes in brand-name drug prices and patient out-of-pocket costs.
10.1001/jamanetworkopen.2021.8816 · 2021
Lowering drug prices in the US—look within, not abroad.
10.1001/jama.2025.12324 · 2025
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.